美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Parabilis Medicines

36.88

+1.163.25%

盤後：36.880.00000.00%19:56 EDT

成交量：97.11萬

成交額：3,622.11萬

市值：45.73億

市盈率：-1.57

高：38.92

開：36.19

低：35.37

收：35.72

52周最高：41.49

52周最低：24.51

股本：1.24億

流通股本：3,350.00萬

量比：1.96

換手率：2.90%

股息：- -

股息率：- -

每股收益(TTM):-23.4458

每股收益(LYR):-60.0402

淨資產收益率：--

總資產收益率：--

市淨率：4.36

市盈率(LYR):-0.61

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Parabilis Medicines任命資深藥物開發專家Craig L. Tendler博士為董事會成員

Parabilis Medicines任命資深藥物開發專家Craig L. Tendler醫學博士為董事會成員

Parabilis Medicines 第二季度末手握11億美元現金及等價物，預計資金可支撐運營至2030年

美國銀行全球研究首次覆蓋Parabilis Medicines，給予買入評級及45美元目標價

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/PBLS"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PBLS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBLS\",,,,,undefined,":{"symbol":"PBLS","market":"US","secType":"STK","nameCN":"Parabilis Medicines","latestPrice":36.88,"timestamp":1789588800000,"preClose":35.72,"halted":0,"volume":971054,"hourTrading":{"tag":"盘后","latestPrice":36.88,"preClose":36.88,"latestTime":"19:56 EDT","volume":3011,"amount":111080.69,"timestamp":1789602997330,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03247480403135509,"floatShares":33500000,"shares":124000000,"eps":-23.44581,"marketStatus":"已收盤","change":1.16,"latestTime":"09-16 16:00:00 EDT","open":36.19,"high":38.915,"low":35.3709,"amount":36221106.580064,"amplitude":0.099219,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-23.44581,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":5,"adr":0,"listingDate":1781064000000,"exchange":"NASDAQ","adjPreClose":35.72,"preHourTrading":{"tag":"盘前","latestPrice":36.43,"preClose":35.72,"latestTime":"08:25 EDT","volume":8,"amount":287.75,"timestamp":1789561558266,"change":0.71,"changeRate":0.019877,"amplitude":0.055991},"postHourTrading":{"tag":"盘后","latestPrice":36.88,"preClose":36.88,"latestTime":"19:56 EDT","volume":3011,"amount":111080.69,"timestamp":1789602997330,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.961389,"impliedVol":0.6935,"impliedVolPercentile":0.6512},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBLS\",,,,,undefined,":{"symbol":"PBLS","floatShares":33500000,"roa":"--","roe":"--","lyrEps":-60.040199,"volumeRatio":1.961389,"shares":124000000,"dividePrice":0,"high":38.915,"amplitude":0.099219,"preClose":35.72,"low":35.3709,"week52Low":24.51,"pbRate":"4.36","psRate":"30899.46","week52High":41.4899,"institutionHeld":0,"latestPrice":36.88,"eps":-23.44581,"divideRate":0,"volume":971054,"delay":0,"ttmEps":-23.44581,"open":36.19,"prevYearClose":20,"prevWeekClose":36.88,"prevMonthClose":39.01,"prevQuarterClose":27.37,"fiveDayClose":38.76,"twentyDayClose":39.35,"sixtyDayClose":27.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBLS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"PBLS","fiscalQuarterEnding":"2026/06","expectedEps":-0.16,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-2.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBLS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBLS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1786766400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PBLS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PBLS","date":"2026-09-15","current":-1.572989,"percent":0.538462,"low":-31.159897,"twenty":-28.671719,"median":-26.487161,"eighty":-23.423744,"high":-15.535256,"avg":-26.157708,"sd":2.915634,"marketCap":4466961958},"quantilePoints":[{"date":"2026-06-12","current":-23.423744,"twenty":-24.021896,"median":-23.423744,"eighty":-18.690651,"marketCap":3580998591},{"date":"2026-06-18","current":-21.681158,"twenty":-23.280127,"median":-22.147598,"eighty":-21.001488,"marketCap":3314593719},{"date":"2026-06-26","current":-21.956025,"twenty":-22.933884,"median":-22.426629,"eighty":-21.561216,"marketCap":3356615076},{"date":"2026-07-02","current":-23.122126,"twenty":-23.423744,"median":-22.77646,"eighty":-21.681158,"marketCap":3534887500},{"date":"2026-07-10","current":-25.287743,"twenty":-24.420664,"median":-22.938881,"eighty":-21.956025,"marketCap":3865964860},{"date":"2026-07-17","current":-24.204934,"twenty":-24.912925,"median":-23.706058,"eighty":-22.147598,"marketCap":3700426180},{"date":"2026-07-24","current":-27.328421,"twenty":-25.279414,"median":-24.204934,"eighty":-22.705661,"marketCap":4177941603},{"date":"2026-07-31","current":-26.886968,"twenty":-25.665893,"median":-24.321545,"eighty":-22.738979,"marketCap":4110452756},{"date":"2026-08-07","current":-29.635636,"twenty":-26.527142,"median":-24.625564,"eighty":-22.753971,"marketCap":4530666328},{"date":"2026-08-14","current":-29.710599,"twenty":-28.289622,"median":-24.912925,"eighty":-22.788954,"marketCap":4542126698},{"date":"2026-08-21","current":-28.671719,"twenty":-28.53843,"median":-25.283578,"eighty":-22.890572,"marketCap":4889445639},{"date":"2026-08-28","current":-28.461644,"twenty":-28.506557,"median":-25.662561,"eighty":-22.933884,"marketCap":4853620999},{"date":"2026-09-04","current":-29.519266,"twenty":-28.607972,"median":-26.20813,"eighty":-23.085477,"marketCap":5033979530},{"date":"2026-09-11","current":-26.310178,"twenty":-28.726773,"median":-26.487161,"eighty":-23.303097,"marketCap":4486727276},{"date":"2026-09-15","current":-26.194274,"twenty":-28.671719,"median":-26.487161,"eighty":-23.423744,"marketCap":4466961958}],"updateTime":1789603962192},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBLS\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1121669089","title":"Parabilis Medicines任命資深藥物開發專家Craig L. Tendler博士為董事會成員","url":"https://stock-news.laohu8.com/highlight/detail?id=1121669089","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121669089?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 19:04","pubTimestamp":1787655884,"startTime":"0","endTime":"0","summary":"马萨诸塞州剑桥，2026年8月25日——Parabilis Medicines今日正式宣布，Craig L. Tendler博士将加入公司董事会。Tendler博士的职业生涯亮点颇多。此前，他已担任Parabilis Medicines的科学顾问，此番履新后，他将同时肩负这两个重要角色。\"我们非常高兴欢迎Craig加入Parabilis董事会。在这个关键节点加入Parabilis董事会，我倍感欣喜。目前，Tendler博士还担任TuHURA Biosciences和Predicta Biosciences的董事会成员，并为多家生物技术公司提供科学顾问服务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","LU1861214812.USD","BK4605","PBLS","LU1861219969.SGD","IE00BD6J9T35.USD","LU0348723411.USD","IE00BFMHRM44.USD","LU1720051108.HKD","BK4555","BK4588","LU2360107325.USD","BK4232","LU1861220033.SGD","LU1854103824.USD","BK4141","LU1978683503.SGD","ONG","ONX","BK4585","LU1983260115.SGD","TM","BK4512","03160","BK4099","BK4006","R","LU2357305700.SGD","LU1861215975.USD","LU0124384867.USD","ACP","BK4022","LU2298322129.HKD","COAL","LU1854104046.USD","LU0724618433.USD","BK4139","IE00BZ199S13.USD","LU1720051017.SGD","BK4604","LU1548497426.USD","ON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143247197","title":"Parabilis Medicines任命資深藥物開發專家Craig L. Tendler醫學博士為董事會成員","url":"https://stock-news.laohu8.com/highlight/detail?id=1143247197","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143247197?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 19:01","pubTimestamp":1787655676,"startTime":"0","endTime":"0","summary":"Parabilis Medicines宣布，已正式任命在药物开发领域建树颇丰的Craig L. Tendler医学博士加入公司董事会。Tendler博士拥有数十年的行业经验，其职业生涯横跨多个治疗领域，并在推动创新疗法从早期研究走向商业化方面拥有卓越记录。此次人事任命，被视作公司强化战略领导力的关键一步，旨在加速其管线资产的推进与拓展。Parabilis Medicines方面表示，Tendler博士的深厚专业知识和广泛行业网络，将为公司在复杂多变的生物制药环境中导航提供重要支持。随着Tendler博士的加入，董事会将更加多元，决策视角亦更为丰富，为公司下一阶段的发展注入强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110375422","title":"Parabilis Medicines 第二季度末手握11億美元現金及等價物，預計資金可支撐運營至2030年","url":"https://stock-news.laohu8.com/highlight/detail?id=1110375422","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110375422?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 19:07","pubTimestamp":1786619229,"startTime":"0","endTime":"0","summary":"Parabilis Medicines 在第二季度结束时，所持有的现金、现金等价物以及有价证券总额高达11亿美元。这笔充裕的资金储备，预计将足以支撑公司的运营活动，直至2030年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146739009","title":"美國銀行全球研究首次覆蓋Parabilis Medicines，給予買入評級及45美元目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=1146739009","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146739009?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 19:39","pubTimestamp":1783337956,"startTime":"0","endTime":"0","summary":"美国银行全球研究已开始对生物制药公司Parabilis Medicines进行覆盖分析，并首次给予其股票“买入”评级。该机构为Parabilis Medicines设定了45.00美元的目标股价，显示出对其未来增长潜力的积极预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBLS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PBLS\",params:#limit:6,delay:false,,,undefined,":[]}}